Yong Jiang, PhD
Associate Professor of Oncology | Internal Medicine
VA building 119, Room 201
Graduate: Wayne State University School of Medicine, Ph.D.
Dr. Jiang received his Ph.D. degree from Wayne State University School of Medicine, where he learned and accumulated research experience as a biochemist. His area of expertise is in gene expression regulation, protein purification, protein structure, and biological function analysis. During his postdoctoral training at the MUSC and CCF, he focused on the mechanistic study of TGF-β signaling pathway and Wnt/β-catenin signaling pathway, which are two key pathways for tumorigenesis and metastasis.
Dr. Jiang’s research has been focusing on tumorigenesis regulated by TGF-b and Wnt signaling pathways. His lab is trying to identify the novel factors involved in these two pathways, and further illustrate their functions and the underlying mechanisms in modulating the progression of cancer. His group will determine whether these novel factors can be potential therapeutic targets to cure cancer. Also, His team is designing and engineering exosomes, and further using them as drug-delivery vehicles for the treatment of cancer. His work is aiming to revolutionize therapeutic regimens for cancer.
1. Discover novel therapeutic targets to attenuate metastasis and chemoresistance
2. Develop exosome-mediated targeted therapy for specific and precise treatment of cancer.
3. Improve the efficacy of radionuclide therapy of cancer through specific delivery.
Cancer Biology, Cell Biology, Immunology, and Biochemistry.
1. Elam BM, Musich PR, Davern S, Yao ZQ, Moorman JP, Jiang Y*. The application of radionuclide therapy for the treatment of breast cancer. Frontiers in Nuclear Medicine. 2023. In process.
2. Weaver JW, Zhang J, Rojas J, Musich PR, Yao, Z, Jiang Y*. The application of exosomes in the treatment of triple-negative breast cancer. Frontiers in Molecular Biosciences. 2022 Nov 10; 9: 1022725.
3. Ogbu SC, Rojas S, Weaver J, Musich PR, Zhang J, Yao Z, Jiang Y*. DSTYK enhances chemoresistance in triple-negative breast cancer cells. Cells, 2022 11(1), 97; 11010097
4. Zhang J, Ogbu SC, Musich PR, Thewke DP, Yao ZQ, Jiang Y*. The contribution of endothelial-mesenchymal transition to atherosclerosis. Int. J. Transl. Med. 2021 June; 1(1):39-54.
5. Ogbu SC, Musich P, Zhang J, Yao Z, Howe P, Jiang Y*. The role of Disabled-2 in diseases. Gene. Feb 15: 769: 145202, 2021.
6. Zhang J, Miller Z, Musich P, Thomas A, Yao Z, Xie Q, Howe P, Jiang Y*. DSTYK promotes metastasis and chemoresistance via EMT in colorectal cancer. Frontiers in Pharmacology. September 02, 2020.